Uncategorized
STAT+: Supreme Court rejects challenge to Medicare drug price negotiation
WASHINGTON — The Supreme Court on Monday dealt a major blow to the brand drug industry’s legal campaign against the Medicare drug price negotiation program.
The court declined to take up lawsuits against the program by AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis, and Novo Nordisk. The justices did not give a reason for their decision.
The rejection was not a surprise. The drugmakers lost their appeals in lower courts, and the Supreme Court typically does not take up cases when there is agreement among lower courts.
WASHINGTON — The Supreme Court on Monday dealt a major blow to the brand drug industry’s legal campaign against the Medicare drug price negotiation program.
The court declined to take up lawsuits against the program by AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis, and Novo Nordisk. The justices did not give a reason for their decision.
The rejection was not a surprise. The drugmakers lost their appeals in lower courts, and the Supreme Court typically does not take up cases when there is agreement among lower courts.